PREVENTion of Non-Surgical Bleeding by Management of HeartMate II Patients without Antiplatelet Therapy (PREVENT II) Trial

Mechanical Circulatory Support (MCS) has become a mainstay in the treatment of advanced heart failure refractory to medical therapy, either as bridge to heart transplantation or destination therapy. Two-year survival for destination therapy patients, historically below 20% on medical therapy alone (REMATCH - Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure)1, is now approaching 80%, similar to heart transplant, with the Food and Drug Administration-approved HeartMate 3 (HM3) LVAD2.

Source: The Journal of Heart and Lung Transplantation - May 14, 2020 Category: Transplant Surgery Authors: Ulrich P. Jorde, Jason N. Katz, Paolo C. Colombo, John Stulak, Omar Saeed, Gregory Egnaczyk, Ernest Haeusslein, Patrick McCann, Daniel Crandall, Abi Franke, Robert Adamson, PREVENT II study investigators (Supplemental Table S1) Tags: Research Correspondence Source Type: research